Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

COHERUS BIOSCIENCES, INC.

(CHRS)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-02 pm EST
8.960 USD   +3.58%
01/23Coherus Biosciences : Corporate Presentation – January 2023
PU
01/17Coherus Agrees To Acquire A Biosimilar EYLEA Candidate From Klinge Biopharma
AQ
01/13Coherus Biosciences, Inc. : Other Events (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/27/2023 01/30/2023 01/31/2023 02/01/2023 02/02/2023 Date
8.34(c) 8.14(c) 8.48(c) 8.65(c) 8.96 Last
916 787 919 492 701 848 922 539 943 577 Volume
-0.12% -2.40% +4.18% +2.00% +3.58% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 214 M - -
Net income 2022 -299 M - -
Net Debt 2022 225 M - -
P/E ratio 2022 -2,27x
Yield 2022 -
Sales 2023 381 M - -
Net income 2023 -124 M - -
Net Debt 2023 370 M - -
P/E ratio 2023 -5,35x
Yield 2023 -
Capitalization 880 M 880 M -
EV / Sales 2022 5,17x
EV / Sales 2023 3,28x
Nbr of Employees 376
Free-Float 92,1%
More Financials
Company
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The CompanyÔÇÖs product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in... 
More about the company
Ratings of Coherus BioSciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about COHERUS BIOSCIENCES, INC.
01/23Coherus Biosciences : Corporate Presentation – January 2023
PU
01/17Coherus Agrees To Acquire A Biosimilar EYLEA Candidate From Klinge Biopharma
AQ
01/13Coherus Biosciences, Inc. : Other Events (form 8-K)
AQ
01/10Transcript : Coherus BioSciences, Inc. Presents at 41st Annual J.P. Morgan He..
CI
01/09Coherus Biosciences : JP Morgan Presentation – January 2023
PU
01/09Coherus BioSciences to Acquire US Commercial Rights to Eylea Biosimilar; Shares Down
MT
01/09Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea« Biosimilar FYB203 ..
GL
01/09Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea« Biosimilar FYB203 ..
AQ
01/04Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Con..
GL
01/04Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Con..
GL
2022Coherus BioSciences Shares Slip 9.6% on Lack of FDA Response to Toripalimab Application
DJ
2022Coherus BioSciences Says Action on Toripalimab Cancer Treatment Application Delayed by ..
MT
2022Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License ..
AQ
2022Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License ..
CI
2022Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License ..
AQ
More news
News in other languages on COHERUS BIOSCIENCES, INC.
01/09Coherus BioSciences va acquérir les droits commerciaux américains du biosimilaire d'Eyl..
2022Coherus BioSciences déclare que l'action sur la demande de traitement du cancer par le ..
2022Junshi Biosciences et Coherus font le point sur l'examen par la FDA de la demande de li..
2022Coherus BioSciences, Inc. annonce ses résultats pour le troisième trimestre et les neuf..
2022Shanghai Junshi Biosciences Co., Ltd. et Coherus BioSciences, Inc. annoncent la publica..
More news
Analyst Recommendations on COHERUS BIOSCIENCES, INC.
More recommendations
ETFs positioned on COHERUS BIOSCIENCES, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Genomics Immunology and Healthcare ...1.28%0.26%World
Direxion Fallen Knives ETF - USD0.81%-9.78%-NC
Invesco S&P SmallCap Health Care ETF - USD0.59%0.50%United_States
Global X S&P Biotech ETF - AUD0.4%-1.19%-United_States
SPDR S&P Biotech ETF - USD0.4%0.09%United_States
More ETFs positioned on COHERUS BIOSCIENCES, INC.
Chart COHERUS BIOSCIENCES, INC.
Duration : Period :
Coherus BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COHERUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 8,96 $
Average target price 17,75 $
Spread / Average Target 98,1%
EPS Revisions
Managers and Directors
Denny M. Lanfear Chairman, President & Chief Executive Officer
McDavid Stilwell Chief Financial Officer
Vladimir Vexler Chief Scientific Officer
Richard L. Hameister Chief Technical Officer
Rosh Dias Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
COHERUS BIOSCIENCES, INC.9.22%849
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.17.28%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436